Ivonescimab (SMT112)
PD-1/VEGF Bispecific

1. Akeso. November 13, 2022. Akeso’s Ivonescimab (PD-1/VEGF Bispecific Antibody, AK112) Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China.
[Press Release]. https://www.akesobio.com/en/media/akeso-news/20221113.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.

It is currently being investigated in Phase III clinical studies.